Azeliragon

Drug Profile

Azeliragon

Alternative Names: PF-04494700; PF-4494700; TTP-488

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TransTech Pharma
  • Developer Pfizer; TransTech Pharma; vTv Therapeutics LLC
  • Class Antidementias; Diethylamines; Imidazoles; Small molecules
  • Mechanism of Action Advanced glycosylation end-product receptor antagonists; Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 04 Aug 2017 vTv Therapeutics has patent protection for azeliragon in USA
  • 16 Jul 2017 Pharmacokinetics and safety data of azeliragon in healthy subjects presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 16 Jul 2017 Pharmacokinetics data from pooled analysis in Healthy volunteers study, Alzheimer’s disease, Type 2 diabetes and persistent albuminuria studies presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top